0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Human Health Effects Nanoplastics Policy & Risk Sign in to save

Peptide-Based Nanoparticles for Systemic Extrahepatic Delivery of Therapeutic Nucleotides

International Journal of Molecular Sciences 2023 19 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 55 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Samuel A. Wickline, Kirk K. Hou, Hua Pan

Summary

This review explores how peptide-based nanoparticles can be used to deliver therapeutic genetic material to organs beyond the liver after being injected into the bloodstream. Researchers summarize the mechanisms behind how these nanoparticles self-assemble, enter cells, and escape cellular compartments to reach their targets. The findings point to promising possibilities for using these delivery systems in treating diseases that current approaches struggle to reach.

Study Type In vivo

Peptide-based nanoparticles (PBN) for nucleotide complexation and targeting of extrahepatic diseases are gaining recognition as potent pharmaceutical vehicles for fine-tuned control of protein production (up- and/or down-regulation) and for gene delivery. Herein, we review the principles and mechanisms underpinning self-assembled formation of PBN, cellular uptake, endosomal release, and delivery to extrahepatic disease sites after systemic administration. Selected examples of PBN that have demonstrated recent proof of concept in disease models in vivo are summarized to offer the reader a comparative view of the field and the possibilities for clinical application.

Share this paper